Literature DB >> 20737011

Annexin V Release and Transmembrane Mitochondrial Potential during Storage of Apheresis-Derived Platelets Treated for Pathogen Reduction.

Susanne M Picker1, Larissa Oustianskaia, Volker Schneider, Birgit S Gathof.   

Abstract

BACKGROUND: In vitro function of stored platelet (PLT) con-centrates was analyzed after applying two different techniques of pathogen reduction technology (PRT) treatment, which could increase cellular injury during processing and storage.
METHODS: Nine triple-dose PLT apheresis donations were split into 27 single units designated to riboflavin-UVB (M) or psoralen-UVA (I) treatment or remained untreated (C). Throughout 8 days of storage, samples were analyzed for annexin V release, the mitochondrial transmembrane potential (Deltapsi) and some classical markers of PLT quality (pH, LDH release, hypotonic shock response (HSR)).
RESULTS: PLT count and LDH release of all units maintained initial ranges. All units exhibited a decrease in pH and HSR and an increase in annexin V release and Deltapsi disruption. Notably, throughout the entire storage period, annexin V release re-mained lowest in M units. Throughout 7 days of storage, M units remained comparable to C units (p > 0.05), whereas inferior values were observed with I units. Here, differences to C units reached significance by day 1 (pH: p < 0.0001), day 5 (annexin V release: p < 0.014), and day 7 (HSR, Deltapsi: p </= 0.003). After PRT treatment, annexin V release and Deltapsi disruption were significantly (p < 0.001) correlated with pH and HSR.
CONCLUSION: During storage, all units showed a de-crease in HSR and an increase in acidity, annexin V release and Deltapsi disruption. While M units remained comparable to C units, I units demonstrated significantly inferior values during terminal storage. This could have resulted from differences in PRT treatment or simply be due to differences in storage media and should be analyzed for clinical relevance in future investigations.

Entities:  

Year:  2010        PMID: 20737011      PMCID: PMC2914403          DOI: 10.1159/000264666

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  22 in total

1.  The mechanism of apoptosis in human platelets during storage.

Authors:  J Li; Y Xia; A M Bertino; J P Coburn; D J Kuter
Journal:  Transfusion       Date:  2000-11       Impact factor: 3.157

2.  The mitochondrial membrane potential in human platelets: a sensitive parameter for platelet quality.

Authors:  Arthur J Verhoeven; Robin Verhaar; Eric G W Gouwerok; Dirk de Korte
Journal:  Transfusion       Date:  2005-01       Impact factor: 3.157

3.  Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.

Authors:  Susanne M Picker; Alexander Steisel; Birgit S Gathof
Journal:  Transfusion       Date:  2008-05-29       Impact factor: 3.157

4.  Continuous analysis of the mechanism of activated transbilayer lipid movement in platelets.

Authors:  P Williamson; E M Bevers; E F Smeets; P Comfurius; R A Schlegel; R F Zwaal
Journal:  Biochemistry       Date:  1995-08-22       Impact factor: 3.162

Review 5.  Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis.

Authors:  C P Reutelingsperger; W L van Heerde
Journal:  Cell Mol Life Sci       Date:  1997-06       Impact factor: 9.261

6.  Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.

Authors:  S Perez-Pujol; R Tonda; M Lozano; B Fuste; I Lopez-Vilchez; A M Galan; J Li; R Goodrich; G Escolar
Journal:  Transfusion       Date:  2005-06       Impact factor: 3.157

7.  Annexins I to VI: quantitative determination in different human cell types and in plasma after myocardial infarction.

Authors:  J Römisch; E Schüler; B Bastian; T Bürger; F G Dunkel; A Schwinn; A A Hartmann; E P Pâques
Journal:  Blood Coagul Fibrinolysis       Date:  1992-02       Impact factor: 1.276

8.  Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.

Authors:  Susanne M Picker; Alexander Steisel; Birgit S Gathof
Journal:  Transfus Apher Sci       Date:  2009-02-23       Impact factor: 1.764

9.  Changes in membrane phospholipid distribution during platelet activation.

Authors:  E M Bevers; P Comfurius; R F Zwaal
Journal:  Biochim Biophys Acta       Date:  1983-12-07

10.  Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.

Authors:  S M Picker; L Oustianskaia; V Schneider; B S Gathof
Journal:  Vox Sang       Date:  2009-03-18       Impact factor: 2.144

View more
  4 in total

1.  As for the Past, as for 2010.

Authors:  Peter Schlenke; Walter Sibrowski
Journal:  Transfus Med Hemother       Date:  2010-02       Impact factor: 3.747

2.  In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step.

Authors:  Mélanie Abonnenc; Giona Sonego; Julie Kaiser-Guignard; David Crettaz; Michel Prudent; Jean-Daniel Tissot; Niels Lion
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

3.  Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.

Authors:  Susanne Marschner; Raymond Goodrich
Journal:  Transfus Med Hemother       Date:  2011-01-31       Impact factor: 3.747

4.  Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.

Authors:  Simona Stivala; Sara Gobbato; Laura Infanti; Martin F Reiner; Nicole Bonetti; Sara C Meyer; Giovanni G Camici; Thomas F Lüscher; Andreas Buser; Jürg H Beer
Journal:  Haematologica       Date:  2017-07-20       Impact factor: 9.941

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.